Company

Hoffmann-La Roche

2 signals

Disease Area

Source

2 of 2 signals

ClinicalTrials14 Apr 2026·Phase 3● 7/10i

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes

RO7795068, a dual GLP-1/GIP receptor agonist from Roche, is being tested versus placebo for weight management in people with obesity or overweight and type 2 diabetes. Phase 3 trial targets 1,600 participants over 72 weeks in a randomized, double-blind, placebo-controlled design. This positions Roche to compete directly with Eli Lilly's tirzepatide (Mounjaro/Zepbound) in the dual incretin mechanism space across both diabetes and obesity indications. The trial represents Roche's first major entry into the competitive GLP-1 obesity market dominated by Novo Nordisk and Eli Lilly.

GLP-1Weight lossType 2 diabetesDrug comparisonsHoffmann-La Roche Eli Lilly

ClinicalTrials7 Apr 2026·Phase 3● 6/10i

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes

Phase 3 trial testing RO7795068, a dual GLP-1/GIP receptor agonist, versus placebo for weight management in people with obesity or overweight without type 2 diabetes. The study will enroll 2,000 participants over 72 weeks to assess percent change in body weight. Roche is entering the competitive weight loss market currently dominated by Novo Nordisk's Wegovy and Eli Lilly's Zepbound, targeting people without diabetes who represent the largest obesity population. Completion in July 2028 positions this as a potential third major dual-hormone option if successful.

GLP-1Weight lossHoffmann-La Roche